Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/27524
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Durez, Patrick | - |
dc.contributor.author | Vanthuyne, Marie | - |
dc.contributor.author | Soyfoo, Muhammad S. | - |
dc.contributor.author | Hoffman, Ilse | - |
dc.contributor.author | Malaise, Michel | - |
dc.contributor.author | GEUSENS, Piet | - |
dc.date.accessioned | 2018-12-18T15:34:09Z | - |
dc.date.available | 2018-12-18T15:34:09Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | ACTA CLINICA BELGICA, 72(6), p. 424-428 | - |
dc.identifier.issn | 1784-3286 | - |
dc.identifier.uri | http://hdl.handle.net/1942/27524 | - |
dc.description.abstract | Objectives: The GO-MORE trial (NCT00975130) was a phase 3 study in 40 countries evaluating the efficacy and safety of golimumab as add-on therapy in biologic-naive adults with active rheumatoid arthritis despite stable treatment with disease-modifying anti-rheumatic drugs. To inform local practice in Belgium and examine the role of baseline disease activity in treatment response, we compared the efficacy of golimumab in the Belgian subpopulation and the rest of the world. Methods: Baseline disease activity and six-month efficacy rates in the GO-MORE trial were compared for the Belgian subpopulation and the rest of the world by t-tests and chi-squared tests. Results: Except for functional impairment, all measures of baseline disease activity were significantly lower (p < 0.0001) in the Belgian population (n = 123) than in the rest of the world (n = 3157). At month six, the rate of good/moderate EULAR response was similar in Belgium and the rest of the world (78.9% vs. 82.2%; p = 0.34), but remission rates were higher in Belgium according to the DAS28-ESR (43.1% vs. 23.2%; p < 0.0001) and Simplified Disease Activity Index (22.0% vs. 13.8%; p = 0.01). Rates of low DAS28-ESR disease activity were also higher in Belgium (54.5% vs. 36.8%; p < 0.0001). Within the Belgian subpopulation, efficacy measures were not significantly different between patients with moderate (n = 73) and high baseline activity (n = 49). Rates of functional impairment at month six did not differ between the two populations. Conclusion: In the Belgian population of the GO-MORE trial, baseline disease activity was lower and six-month remission rates were higher than in the rest of the world. | - |
dc.description.sponsorship | MSD-Belgium | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject.other | Rheumatoid arthritis; Golimumab; Anti-rheumatic agents; Biological products | - |
dc.subject.other | Rheumatoid arthritis; Golimumab; Anti-rheumatic agents; Biological products | - |
dc.title | Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 428 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 424 | - |
dc.identifier.volume | 72 | - |
local.format.pages | 5 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Durez, Patrick] Catholic Univ Louvain, Inst Rech Expt & Clin, Clin Univ St Luc, Rheumatol Dept, Brussels, Belgium. [Durez, Patrick] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Pathol Rhumatismales, Brussels, Belgium. [Vanthuyne, Marie] Catholic Univ Louvain, Clin Univ St Luc, Rheumatol Dept, Brussels, Belgium. [Soyfoo, Muhammad S.] ULB Hop Erasme, Serv Rhumatol, Brussels, Belgium. [Hoffman, Ilse] Sint Augustinus, GZA, Dienst Reumatol, Antwerp, Belgium. [Malaise, Michel] CHU Sart Tilman, Serv Rhumatol, Liege, Belgium. [Geusens, Piet] UH & MUMC, Genk, Belgium. [Geusens, Piet] ReumaClin, Genk, Belgium. | - |
local.publisher.place | ABINGDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1080/17843286.2017.1314079 | - |
dc.identifier.isi | 000415688800008 | - |
item.accessRights | Restricted Access | - |
item.validation | ecoom 2018 | - |
item.contributor | Durez, Patrick | - |
item.contributor | Vanthuyne, Marie | - |
item.contributor | Soyfoo, Muhammad S. | - |
item.contributor | Hoffman, Ilse | - |
item.contributor | Malaise, Michel | - |
item.contributor | GEUSENS, Piet | - |
item.fullcitation | Durez, Patrick; Vanthuyne, Marie; Soyfoo, Muhammad S.; Hoffman, Ilse; Malaise, Michel & GEUSENS, Piet (2017) Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study. In: ACTA CLINICA BELGICA, 72(6), p. 424-428. | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1784-3286 | - |
crisitem.journal.eissn | 2295-3337 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
durez2017.pdf Restricted Access | Published version | 642.27 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
1
checked on Oct 14, 2024
Page view(s)
56
checked on Sep 7, 2022
Download(s)
48
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.